Vortioxetine for Cognitive Enhancement in Major Depression: From Animal Models to Clinical Research

Vortioxetine for Cognitive Enhancement in Major Depression: From Animal Models to Clinical Research

Objectives: Vortioxetine has already shown its efficacy in the acute and long-term treatment of major depressive disorder (MDD) and its potential interest in the prevention of relapse. The aim of this study was to review the current status of knowledge regarding its cognitive effects.Methods: We con...

Full description

Bibliographic Details
Main Authors:	Djamila Bennabi, Emmanuel Haffen, Vincent Van Waes
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2019-11-01
Series:	Frontiers in Psychiatry
Subjects:	major depressive disorder vortioxetine cognition humans animals
Online Access:	https://www.frontiersin.org/article/10.3389/fpsyt.2019.00771/full

Similar Items

Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder
by: McIntyre RS, et al.
Published: (2021-02-01)

The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder
by: Bing Cao, et al.
Published: (2019-01-01)

Vortioxetine usage in an elderly patient with major depressive disorder and accompanied by multiple physical conditions: A case report
by: Xiaoman Wang, et al.
Published: (2023-12-01)

Effectiveness of vortioxetine for major depressive disorder in real-world clinical practice: US cohort results from the global RELIEVE study
by: Gregory Mattingly, et al.
Published: (2023-01-01)

Efficacy of vortioxetine monotherapy compared with combined therapy vortioxetine and olanzapine in the treatment of major depression – first results
by: Oppa M., et al.
Published: (2017-09-01)

DEPRESSION AND COGNITIVE DISTURBANCES: EXPERIENCE OF VORTIOXETINE USE IN NEUROLOGIC PRACTICE
by: Y. E. Azimova
Published: (2017-07-01)

Effectiveness and Safety of Vortioxetine for Major Depressive Disorder in Real-World Clinical Practice: Results from the Single-Arm RELIEVE China Study
by: Wang G, et al.
Published: (2022-08-01)

A Case of Major Depression with Burning Mouth Syndrome and Tinnitus Successfully Treated with Vortioxetine
by: Yoshimura R, et al.
Published: (2021-04-01)

Systematic Review and Meta-Analysis of Vortioxetine for the Treatment of Major Depressive Disorder in Adults
by: Xinyan Zhang, et al.
Published: (2022-06-01)

Experience with vortioxetine in the treatment of post-stroke depression
by: I. A. Strelnikova, et al.
Published: (2020-02-01)

Effectiveness of vortioxetine in patients with major depressive disorder and comorbid Alzheimer’s disease in routine clinical practice: An analysis of a post-marketing surveillance study in South Korea
by: Eduardo Cumbo, et al.
Published: (2023-01-01)

A Feasibility Study of Patients with Major Depression and Substance Use Disorders: Vortioxetine as Maintenance Treatment
by: Basurte-Villamor I, et al.
Published: (2022-05-01)

Effectiveness of Vortioxetine in Patients with Major Depressive Disorder in Real-World Clinical Practice in Italy: Results from the RELIEVE Study
by: De Filippis S, et al.
Published: (2022-08-01)

Real-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects
by: Eugenia Papalexi, et al.
Published: (2022-08-01)

Early Improvement with Vortioxetine Predicts Response and Remission: A Post Hoc Analysis of Data from a Clinical Trial Conducted in Japan
by: Inoue T, et al.
Published: (2021-12-01)

Vortioxetine Modulates the Regional Signal in First-Episode Drug-Free Major Depressive Disorder at Rest
by: Shihong Xiong, et al.
Published: (2022-06-01)

Effectiveness of Vortioxetine in Patients with Major Depressive Disorder in Real-World Clinical Practice: French Cohort Results from the Global RELIEVE Study
by: Polosan M, et al.
Published: (2022-08-01)

Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a “real-world” chart review study
by: Domenico De Berardis, et al.

Emotional blunting and cognitive profile in elderly depressed patients in treatment with vortioxetine
by: F. Franza, et al.
Published: (2021-04-01)

Comparison of the efficacy of the multimodal serotonergic antidepressants trazodone and vortioxetine in the treatment of patients with endogenous depression: A meta-analysis of double-blind randomized placebo-controlled trials
by: D. S. Danilov
Published: (2017-03-01)

Safety and effectiveness of vortioxetine for major depressive disorder: Real-world evidence from a population-based study in South Korea
by: Seok Woo Moon, et al.
Published: (2023-03-01)

Case Report: Vortioxetine in the Treatment of Depressive Symptoms in Patients With Epilepsy—Case Series
by: Marcin Siwek, et al.
Published: (2022-03-01)

Effects of Vortioxetine on Sleep Architecture of Adolescents with Major Depressive Disorder
by: Zuzana Mlyncekova, et al.
Published: (2023-10-01)

Vortioxetine Improves Depressive Symptoms and Cognition in Parkinson’s Disease Patients with Major Depression: An Open-Label Prospective Study
by: Diego Santos García, et al.
Published: (2022-10-01)

Effectiveness of vortioxetine for winter depression in bipolar disorder: A case report
by: Yusei Yamaguchi, et al.
Published: (2024-03-01)

The use of vortioxetine for depression in patients with Parkinson's disease in the early and advanced stages of the disease
by: I. V. Miliukhina
Published: (2020-10-01)

Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo
by: Célia Fourrier, et al.
Published: (2018-08-01)

Cognitive impairment in depression: recent advances and novel treatments
by: Perini G, et al.
Published: (2019-05-01)

Vortioxetine treatment for major depressive disorder with the co-morbidity of irritable bowel syndrome with diarrhoea: a case report
by: Orkun Aydin, et al.
Published: (2018-01-01)

Efficiency and safety of Vortioxetine in the treatment of depressive disorders in cardiac patients
by: N. V. Filippova, et al.
Published: (2023-06-01)

Review of a New Multimodal Antidepressant Vortioxetine
by: Oppa M, et al.
Published: (2016-08-01)

An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder
by: Anish Shah, et al.
Published: (2018-05-01)

Vortioxetine for depression treatment in hospital setting: experience from a single psychiatric hospital
by: O. V. Limankin, et al.
Published: (2020-10-01)

Comparative efficacy and safety of escitalopram, desvenlafaxine, and vortioxetine in the acute treatment of anxious depression: A randomized rater-blinded, 6-week clinical trial
by: K.-S. Oh, et al.
Published: (2022-06-01)

Naturalistic and Uncontrolled Pilot Study on the Efficacy of Vortioxetine in Binge Eating Disorder With Comorbid Depression
by: Cristina Segura-Garcia, et al.
Published: (2021-03-01)

Serum insulin-like growth factor-1 as a potential marker for MDD diagnosis, its clinical characteristics, and treatment efficacy validation: data from an open-label vortioxetine study
by: Oleg A. Levada, et al.
Published: (2020-05-01)

Tolerability of vortioxetine compared to selective serotonin reuptake inhibitors in older adults with major depressive disorder (VESPA): a randomised, assessor-blinded and statistician-blinded, multicentre, superiority trialResearch in context
by: Giovanni Ostuzzi, et al.
Published: (2024-03-01)

The impact of dose on the real-world effectiveness of vortioxetine in outpatients with mdd in greece
by: E. Papalexi, et al.
Published: (2021-04-01)

Improved cognitive function in patients with major depressive disorder after treatment with vortioxetine: A EEG study
by: Hong Kim, et al.
Published: (2022-03-01)

Goal Attainment Scaling for Depression: Validation of the Japanese GAS-D Tool in Patients with Major Depressive Disorder
by: Kato M, et al.
Published: (2024-01-01)